|Rapid review complete
|For the treatment of chronic kidney disease
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is not recommended. The NCPE recommends that dapaglifozin not be considered for reimbursement at the submitted price.*
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.